SEROTONIN RECEPTOR SUBTYPES INVOLVED IN THE ELEVATION OF SERUM CORTICOSTERONE CONCENTRATION IN RATS BY DIRECT-ACTING AND INDIRECT-ACTING SEROTONIN AGONISTS

被引:97
作者
FULLER, RW
SNODDY, HD
机构
[1] Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN
关键词
8-Hydroxy-2-(di-n-propylamino)tetralin; Corticosterone; Fluoxetine; L-5-Hydroxytryptophan; Quipazine; Serotonin; ρ-Chloroamphetamine;
D O I
10.1159/000125586
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The serum corticosterone concentration in rats was increased by injection of quipazine, a relatively nonselective serotonin (5-hydroxytryptamine; 5-HT) agonist, or 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a serotonin agonist selective for the 5-HT1A ia subtype of receptor. The quipazine-induced increase in serum corticosterone was antagonized by 17 different serotonin antagonists; of these, MDL 11939, pirenperone, setoperone, mianserin, LY 281067, ketanserin. ritanserin and clozapine have relatively selective affinity for the 5-HT2 subtype of receptor. The 8-OFl-DPAT-induced increase in serum corticosterone was not antagonized by metergoline, the most potent antagonist of the quipazine effect, but was antagonized by pindolol or penbutolol, 5-HT1A receptor antagonists. Pindolol did not block the effect of quipazine. The results support earlier evidence that serum corticosterone concentration in rats can be increased by activation of either 5-HTia or 5-HT2 receptors. Indirect-acting serotonin agonists - fluoxetine, L-5-hydroxytryptophan and ρ;-chloroamphetamine - also increased serum corticosterone concentrations. The increases elicited by those agents, which earlier had been reported not to be blocked by metergoline pretreatment, also were not blocked by pretreatment with pindolol or with the combination of metergoline and pindolol. Thus, an involvement of a specific serotonin receptor subtype in the actions of these indirect agonists has not been established. © 1990 S. Karger AG, Basel.
引用
收藏
页码:206 / 211
页数:6
相关论文
共 25 条
[1]  
BOAVENTURA AM, 1987, NOV INT C BEH PHARM
[2]  
COHEN ML, 1988, J PHARMACOL EXP THER, V244, P106
[3]  
CONN PJ, 1986, P NATL ACAD SCI USA, V83, P3086
[4]   PHARMACOLOGICAL EFFECTS OF MDL-11,939 - A SELECTIVE, CENTRALLY ACTING ANTAGONIST OF 5-HT2 RECEPTORS [J].
DUDLEY, MW ;
WIECH, NL ;
MILLER, FP ;
CARR, AA ;
CHENG, HC ;
ROEBEL, LE ;
DOHERTY, NS ;
YAMAMURA, HI ;
URSILLO, RC ;
PALFREYMAN, MG .
DRUG DEVELOPMENT RESEARCH, 1988, 13 (01) :29-43
[5]  
FULLER RW, 1986, J PHARMACOL EXP THER, V239, P454
[6]  
FULLER RW, 1975, RES COMMUN CHEM PATH, V10, P193
[7]   EFFECTS OF METERGOLINE AND OTHER SEROTONIN RECEPTOR ANTAGONISTS ON SERUM CORTICOSTERONE IN RATS [J].
FULLER, RW ;
SNODDY, HD .
ENDOCRINOLOGY, 1979, 105 (04) :923-928
[8]   PHARMACOLOGIC EVIDENCE FOR A SEROTONIN NEURAL PATHWAY INVOLVED IN HYPOTHALAMUS-PITUITARY-ADRENAL FUNCTION IN RATS [J].
FULLER, RW ;
SNODDY, HD ;
MOLLOY, BB .
LIFE SCIENCES, 1976, 19 (03) :337-345
[9]  
FULLER RW, 1984, RES COMMUN CHEM PATH, V46, P151
[10]   SEROTONERGIC STIMULATION OF PITUITARY-ADRENOCORTICAL FUNCTION IN RATS [J].
FULLER, RW .
NEUROENDOCRINOLOGY, 1981, 32 (02) :118-127